https://www.live-feeds.com/feed/roche-s-glp-1-gip-drug-hits-in-phase-2-diabetes-trial-fueling-best-in-disease-hopesContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/roche-s-glp-1-gip-drug-hits-in-phase-2-diabetes-trial-fueling-best-in-disease-hopeshttps://www.live-feeds.com/feed/roche-s-glp-1-gip-drug-hits-in-phase-2-diabetes-trial-fueling-best-in-disease-hopes#u83144Fri, 25 Sep 2026 00:11:10 +0000Roche reported positive results from a phase 2 trial of its GLP-1/GIP agonist in overweight patients with diabetes. The drug improved blood sugar control and achieved a 15.5% reduction in body weight. This second mid-stage win has led analysts to describe the treatment as competitive. The shot was originally acquired through Roche's purchase of Carmot Therapeutics. These results support the company's goal of developing a best-in-disease therapy for obesity and diabetes management.Why it mattersThe GLP-1/GIP class of drugs targets two different hormone receptors to improve metabolic h